Organoidsciences Ltd
476040
Company Profile
Business description
Organoidsciences Ltd is a three-dimensional cell structure created by self-organization. It has two products, ATORM, which is a medicine applied to various diseases and was developed using organoids derived from tissues such as intestines and salivary glands. ODISEI, an organoid-based new material evaluation solution, is an evaluation service for predicting the effects of various new materials, such as new drugs, foods, and cosmetics, when applied to the human body, and was developed using organoids for tumors, viruses, intestines, and skin.
Contact
338 Pangyo-ro
6th floor, Bundang-gu
Gyeonggi-do
Seongnam-si
KORT: +82 27072024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.80 | 116.00 | 1.30% |
| CAC 40 | 7,868.40 | 46.40 | 0.59% |
| DAX 40 | 24,482.99 | 112.06 | 0.46% |
| Dow JONES (US) | 44,484.49 | 229.71 | 0.52% |
| FTSE 100 | 8,991.50 | 18.86 | 0.21% |
| HKSE | 24,800.07 | 301.12 | 1.23% |
| NASDAQ | 20,885.65 | 155.16 | 0.75% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
| S&P 500 | 6,297.36 | 33.66 | 0.54% |
| S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
| SSE Composite Index | 3,534.48 | 17.66 | 0.50% |